The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Spinal and Bulbar Muscular Atrophy Treatment Market Research Report 2025
Synopsis
SBMA, mainly manifested as systemic muscle atrophy, paralysis and systemic muscle bundle tremor, patients with systemic muscle weakness, especially the weakness of the two lower limbs to walk, tongue muscle atrophy is usually one of the main symptoms.
The global Spinal and Bulbar Muscular Atrophy Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Spinal and Bulbar Muscular Atrophy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal and Bulbar Muscular Atrophy Treatment.
Report Scope
The Spinal and Bulbar Muscular Atrophy Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Spinal and Bulbar Muscular Atrophy Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Spinal and Bulbar Muscular Atrophy Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Pfizer
GlaxoSmithKline
Johnson & Johnson
Century Pharmaceuticals
Astellas Pharma
Sanofi
Boehringer Ingelheim International
Segment by Type
5α-Reductase Inhibitors
Gonadotropin-releasing Hormone Agonists
Segment by Application
Hospitals
Orthopedic Clinics
Ambulatory Surgical Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Spinal and Bulbar Muscular Atrophy Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
SBMA, mainly manifested as systemic muscle atrophy, paralysis and systemic muscle bundle tremor, patients with systemic muscle weakness, especially the weakness of the two lower limbs to walk, tongue muscle atrophy is usually one of the main symptoms.
The global Spinal and Bulbar Muscular Atrophy Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Spinal and Bulbar Muscular Atrophy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Spinal and Bulbar Muscular Atrophy Treatment.
Report Scope
The Spinal and Bulbar Muscular Atrophy Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Spinal and Bulbar Muscular Atrophy Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Spinal and Bulbar Muscular Atrophy Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Pfizer
GlaxoSmithKline
Johnson & Johnson
Century Pharmaceuticals
Astellas Pharma
Sanofi
Boehringer Ingelheim International
Segment by Type
5α-Reductase Inhibitors
Gonadotropin-releasing Hormone Agonists
Segment by Application
Hospitals
Orthopedic Clinics
Ambulatory Surgical Centers
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Spinal and Bulbar Muscular Atrophy Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 5α-Reductase Inhibitors
1.2.3 Gonadotropin-releasing Hormone Agonists
1.3 Market by Application
1.3.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Orthopedic Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Perspective (2019-2030)
2.2 Spinal and Bulbar Muscular Atrophy Treatment Growth Trends by Region
2.2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Spinal and Bulbar Muscular Atrophy Treatment Historic Market Size by Region (2019-2024)
2.2.3 Spinal and Bulbar Muscular Atrophy Treatment Forecasted Market Size by Region (2025-2030)
2.3 Spinal and Bulbar Muscular Atrophy Treatment Market Dynamics
2.3.1 Spinal and Bulbar Muscular Atrophy Treatment Industry Trends
2.3.2 Spinal and Bulbar Muscular Atrophy Treatment Market Drivers
2.3.3 Spinal and Bulbar Muscular Atrophy Treatment Market Challenges
2.3.4 Spinal and Bulbar Muscular Atrophy Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Spinal and Bulbar Muscular Atrophy Treatment Players by Revenue
3.1.1 Global Top Spinal and Bulbar Muscular Atrophy Treatment Players by Revenue (2019-2024)
3.1.2 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Spinal and Bulbar Muscular Atrophy Treatment Revenue
3.4 Global Spinal and Bulbar Muscular Atrophy Treatment Market Concentration Ratio
3.4.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Spinal and Bulbar Muscular Atrophy Treatment Revenue in 2023
3.5 Spinal and Bulbar Muscular Atrophy Treatment Key Players Head office and Area Served
3.6 Key Players Spinal and Bulbar Muscular Atrophy Treatment Product Solution and Service
3.7 Date of Enter into Spinal and Bulbar Muscular Atrophy Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Spinal and Bulbar Muscular Atrophy Treatment Breakdown Data by Type
4.1 Global Spinal and Bulbar Muscular Atrophy Treatment Historic Market Size by Type (2019-2024)
4.2 Global Spinal and Bulbar Muscular Atrophy Treatment Forecasted Market Size by Type (2025-2030)
5 Spinal and Bulbar Muscular Atrophy Treatment Breakdown Data by Application
5.1 Global Spinal and Bulbar Muscular Atrophy Treatment Historic Market Size by Application (2019-2024)
5.2 Global Spinal and Bulbar Muscular Atrophy Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Spinal and Bulbar Muscular Atrophy Treatment Market Size (2019-2030)
6.2 North America Spinal and Bulbar Muscular Atrophy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2019-2024)
6.4 North America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Spinal and Bulbar Muscular Atrophy Treatment Market Size (2019-2030)
7.2 Europe Spinal and Bulbar Muscular Atrophy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2019-2024)
7.4 Europe Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Size (2019-2030)
8.2 Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Size (2019-2030)
9.2 Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2019-2024)
9.4 Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Size (2019-2030)
10.2 Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Spinal and Bulbar Muscular Atrophy Treatment Introduction
11.1.4 AbbVie Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Spinal and Bulbar Muscular Atrophy Treatment Introduction
11.2.4 Pfizer Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Detail
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Introduction
11.3.4 GlaxoSmithKline Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
11.3.5 GlaxoSmithKline Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Introduction
11.4.4 Johnson & Johnson Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
11.4.5 Johnson & Johnson Recent Development
11.5 Century Pharmaceuticals
11.5.1 Century Pharmaceuticals Company Detail
11.5.2 Century Pharmaceuticals Business Overview
11.5.3 Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Introduction
11.5.4 Century Pharmaceuticals Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
11.5.5 Century Pharmaceuticals Recent Development
11.6 Astellas Pharma
11.6.1 Astellas Pharma Company Detail
11.6.2 Astellas Pharma Business Overview
11.6.3 Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Introduction
11.6.4 Astellas Pharma Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
11.6.5 Astellas Pharma Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Spinal and Bulbar Muscular Atrophy Treatment Introduction
11.7.4 Sanofi Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
11.7.5 Sanofi Recent Development
11.8 Boehringer Ingelheim International
11.8.1 Boehringer Ingelheim International Company Detail
11.8.2 Boehringer Ingelheim International Business Overview
11.8.3 Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Introduction
11.8.4 Boehringer Ingelheim International Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
11.8.5 Boehringer Ingelheim International Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of 5α-Reductase Inhibitors
Table 3. Key Players of Gonadotropin-releasing Hormone Agonists
Table 4. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Region (2019-2024)
Table 8. Global Spinal and Bulbar Muscular Atrophy Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Region (2025-2030)
Table 10. Spinal and Bulbar Muscular Atrophy Treatment Market Trends
Table 11. Spinal and Bulbar Muscular Atrophy Treatment Market Drivers
Table 12. Spinal and Bulbar Muscular Atrophy Treatment Market Challenges
Table 13. Spinal and Bulbar Muscular Atrophy Treatment Market Restraints
Table 14. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Players (2019-2024)
Table 16. Global Top Spinal and Bulbar Muscular Atrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal and Bulbar Muscular Atrophy Treatment as of 2023)
Table 17. Ranking of Global Top Spinal and Bulbar Muscular Atrophy Treatment Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Spinal and Bulbar Muscular Atrophy Treatment Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Spinal and Bulbar Muscular Atrophy Treatment Product Solution and Service
Table 21. Date of Enter into Spinal and Bulbar Muscular Atrophy Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Type (2019-2024)
Table 25. Global Spinal and Bulbar Muscular Atrophy Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Type (2025-2030)
Table 27. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Application (2019-2024)
Table 29. Global Spinal and Bulbar Muscular Atrophy Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share by Application (2025-2030)
Table 31. North America Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 46. AbbVie Company Detail
Table 47. AbbVie Business Overview
Table 48. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Product
Table 49. AbbVie Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 50. AbbVie Recent Development
Table 51. Pfizer Company Detail
Table 52. Pfizer Business Overview
Table 53. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Product
Table 54. Pfizer Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 55. Pfizer Recent Development
Table 56. GlaxoSmithKline Company Detail
Table 57. GlaxoSmithKline Business Overview
Table 58. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Product
Table 59. GlaxoSmithKline Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 60. GlaxoSmithKline Recent Development
Table 61. Johnson & Johnson Company Detail
Table 62. Johnson & Johnson Business Overview
Table 63. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Product
Table 64. Johnson & Johnson Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 65. Johnson & Johnson Recent Development
Table 66. Century Pharmaceuticals Company Detail
Table 67. Century Pharmaceuticals Business Overview
Table 68. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Product
Table 69. Century Pharmaceuticals Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 70. Century Pharmaceuticals Recent Development
Table 71. Astellas Pharma Company Detail
Table 72. Astellas Pharma Business Overview
Table 73. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Product
Table 74. Astellas Pharma Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 75. Astellas Pharma Recent Development
Table 76. Sanofi Company Detail
Table 77. Sanofi Business Overview
Table 78. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Product
Table 79. Sanofi Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 80. Sanofi Recent Development
Table 81. Boehringer Ingelheim International Company Detail
Table 82. Boehringer Ingelheim International Business Overview
Table 83. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Product
Table 84. Boehringer Ingelheim International Revenue in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024) & (US$ Million)
Table 85. Boehringer Ingelheim International Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Type: 2023 VS 2030
Figure 3. 5α-Reductase Inhibitors Features
Figure 4. Gonadotropin-releasing Hormone Agonists Features
Figure 5. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Application: 2023 VS 2030
Figure 7. Hospitals Case Studies
Figure 8. Orthopedic Clinics Case Studies
Figure 9. Ambulatory Surgical Centers Case Studies
Figure 10. Spinal and Bulbar Muscular Atrophy Treatment Report Years Considered
Figure 11. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Region: 2023 VS 2030
Figure 14. Global Spinal and Bulbar Muscular Atrophy Treatment Market Share by Players in 2023
Figure 15. Global Top Spinal and Bulbar Muscular Atrophy Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Spinal and Bulbar Muscular Atrophy Treatment as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Spinal and Bulbar Muscular Atrophy Treatment Revenue in 2023
Figure 17. North America Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Spinal and Bulbar Muscular Atrophy Treatment Market Share by Country (2019-2030)
Figure 19. United States Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Spinal and Bulbar Muscular Atrophy Treatment Market Share by Country (2019-2030)
Figure 23. Germany Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Spinal and Bulbar Muscular Atrophy Treatment Market Share by Region (2019-2030)
Figure 31. China Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Spinal and Bulbar Muscular Atrophy Treatment Market Share by Country (2019-2030)
Figure 39. Mexico Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Market Share by Country (2019-2030)
Figure 43. Turkey Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. AbbVie Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
Figure 46. Pfizer Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
Figure 47. GlaxoSmithKline Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
Figure 48. Johnson & Johnson Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
Figure 49. Century Pharmaceuticals Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
Figure 50. Astellas Pharma Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
Figure 51. Sanofi Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
Figure 52. Boehringer Ingelheim International Revenue Growth Rate in Spinal and Bulbar Muscular Atrophy Treatment Business (2019-2024)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
